News

Applied Clinical Trials Online4h
Phase IIIb VOLITION Trial Shows Strong Patient Preference for Long-Acting HIV Therapy After Rapid Suppression on Oral Treatment
New data from the VOLITION study reveal that 89% of treatment-naïve individuals with HIV chose to switch to long-acting cabotegravir and rilpivirine after achieving viral suppression with oral DTG/3TC ...
Applied Clinical Trials Online6h
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world ...
Applied Clinical Trials Online23h
Gilead’s Yeztugo Demonstrates Strong HIV Prevention Results in Underserved Populations
Results from the Phase III PURPOSE 1 (NCT04994509) and PURPOSE 2 (NCT04925752) trials highlight Yeztugo’s (lenacapavir) ...